Business Daily.
.
A+ R A-

Newron Receives FDA Orphan Drug Designation for Sarizotan for the Treatment of Rett Syndrome

E-mail Print PDF
MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Newron's sarizotan for the treatment of Rett syndrome.

imageimage
Grow Your Business with Times Media
Business Daily Media